
Actuate Therapeutics is a clinical stage biopharmaceutical company focused on developing therapies for the treatment of high impact, difficult to treat cancers through the inhibition of glycogen synthase kinase-3 (GSK-3). We are developing elraglusib (formerly 9-ING-41), a small molecule that is des... Actuate Therapeutics is a clinical stage biopharmaceutical company focused on developing therapies for the treatment of high impact, difficult to treat cancers through the inhibition of glycogen synthase kinase-3 (GSK-3). We are developing elraglusib (formerly 9-ING-41), a small molecule that is designed to enter cancer cells and block the function of the enzyme GSK-3B. We believe that the blockade of GSK-3B signaling ultimately results in the death of the cancer cells and the regulation of anti-tumor immunity. We have exclusively licensed a portfolio of GSK-3 inhibitors developed in a collaboration between the University of Illinois-Chicago (UIC) and Northwestern University (NU). Show more
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.45 | -6.82852807284 | 6.59 | 6.746 | 5.7 | 75592 | 6.26196003 | CS |
4 | -2.49 | -28.852838934 | 8.63 | 9.005 | 5.5 | 163757 | 6.49419807 | CS |
12 | -1.86 | -23.25 | 8 | 11.99 | 5.5 | 100660 | 8.08107992 | CS |
26 | -1.85 | -23.153942428 | 7.99 | 11.99 | 5.5 | 63444 | 8.00589025 | CS |
52 | 1.14 | 22.8 | 5 | 11.99 | 5 | 52265 | 8.04032679 | CS |
156 | 1.14 | 22.8 | 5 | 11.99 | 5 | 17306 | 8.04032679 | CS |
260 | 1.14 | 22.8 | 5 | 11.99 | 5 | 10890 | 8.04032679 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.